Further multicenter studies with a large sample size are warranted to observe changes in PD-pathognomonic proteins, namely α-synuclein, tau, and Aβ1–42 proteins, in plasma EVs and determine their association with cognitive impairment in patients in the early stages of PD. This evidence concerns the gene MAPT and Parkinson disease.